The class
Genetic proxies for CETP inhibition are linked to lower preeclampsia risk in a Mendelian randomization study (Int J Womens Health 2025)
Original title: Genetic Insights Into Lipid Traits and Lipid-Modifying Drug Targets in Pregnancy Complications: A Two-Sample Mendelian Randomization Study
A two-sample Mendelian randomization study used genetic instruments for lipid traits and lipid-modifying drug targets from the Global Lipids Genetics Consortium, with pregnancy complication outcomes from FinnGen R9, to test causal relationships between lipid traits, drug targets, and pregnancy complications. Increased HDL-cholesterol reduced the incidence of preeclampsia (OR 0.755, 95% CI 0.639-0.891, p=0.001, FDR=0.012) and gestational diabetes mellitus (OR 0.835, 95% CI 0.741-0.942, p=0.003, FDR=0.018). Genetic proxies for CETP inhibition were associated with a decreased risk of preeclampsia (OR 0.863, 95% CI 0.786-0.947, p=0.002, FDR=0.027), while genetic inhibition of HMG-CoA reductase increased preeclampsia risk (OR 1.700, 95% CI 1.189-2.431, p=0.004, FDR=0.036), and genetically mimicked lipoprotein lipase enhancement reduced GDM risk. The authors conclude CETP could be a therapeutic target for preeclampsia prevention.
Original abstract
Background: Dyslipidemia is linked to pregnancy complications, but its causal role remains uncertain. This two-sample Mendelian Randomization (MR) study investigated the causal relationship between lipid traits and pregnancy complications and evaluated the impact of lipid-modifying drug targets.
Methods: Genetic instruments for lipid traits and targets for lipid-modifying drugs were obtained from the Global Lipids Genetics Consortium. Three pregnancy complications' summary statistics came from the FinnGen R9 database. Significant drug targets underwent further analysis using Expression Quantitative Trait Loci data, and mediation analysis identified potential mediators.
Results: Increased high-density lipoprotein cholesterol (HDL-C) reduced the incidence of preeclampsia (OR: 0.755, 95% CI: 0.639-0.891, p=0.001, FDR=0.012) and gestational diabetes mellitus (GDM) (OR: 0.835, 95% CI: 0.741-0.942, p=0.003, FDR=0.018). Genetic proxies for cholesteryl ester transfer protein (CETP) inhibition correlated with a decreased risk of preeclampsia (OR: 0.863, 95% CI: 0.786-0.947, p=0.002, FDR=0.027), while genetic inhibition of HMG-CoA reductase (HMGCR) increased preeclampsia risk (OR: 1.700, 95% CI: 1.189-2.431, p=0.004, FDR=0.036). Genetically mimicking the enhancement of lipoprotein lipase (LPL) related to a reduced risk of GDM (OR: 0.681, 95% CI: 0.560-0.829, p=1.29×10-4, FDR=0.004). Higher LPL expression in subcutaneous adipose tissue also reduced GDM risk (OR: 0.642, 95% CI: 0.454-0.909, p=0.013). Waist circumference (4.2%) and waist-to-hip ratio adjusted by BMI (5.7%) partially mediated LPL's effect on GDM risk.
Conclusion: Elevated HDL-C levels help prevent preeclampsia and GDM. CETP and LPL could be therapeutic targets for preeclampsia and GDM, respectively. However, caution is advised with HMGCR-targeting drugs, as they may increase the preeclampsia risk.
Summary written by cetpinhibition.org from the published abstract; figures as published. Page updated 19 August 2026. Methods.